Infliximab for refractory sarcoidosis

Sarcoidosis Vasc Diffuse Lung Dis. 2001 Mar;18(1):70-4.


Background and aim of work: Tumor necrosis factor-alpha (TNF-alpha) appears to be an important cytokine in the inflammation of sarcoidosis. Infliximab is a chimeric monoclonal antibody which specifically inhibits TNF-alpha. We investigated the efficacy of infliximab for the therapy of chronic, resistant sarcoidosis.

Methods: Patients with persistent symptomatic sarcoidosis despite corticosteroids and immunosuppressive agents were selected for treatment with infliximab. Patients were treated initially and at 2, 4, and 12 weeks with 5 mg/kg of infliximab at each treatment. Index lesions, which had progressed despite corticosteroid therapy, were reevaluated at 16 weeks.

Results: Three patients were treated. In two patients, the index lesion was lupus pernio, which significantly improved with infliximab. The third patient had restrictive lung disease. At week 16, there was a 26% improvement in the vital capacity from pretreatment values. All patients tolerated the treatments well.

Conclusions: Infliximab was associated with significant improvement in chronic sarcoidosis.

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Chronic Disease
  • Drug Resistance
  • Female
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Recurrence
  • Respiratory Function Tests
  • Sarcoidosis / drug therapy*
  • Sarcoidosis / pathology
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Infliximab